Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    Journal Title:  J Blood Med Primary Author:  Abou ... of patients with del(5q) MDS, including reduction in red blood cell transfusion requirements and improvements in quality of ...

    Research Article last updated 03/02/2015 - 2:11pm.

  2. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    Journal Title:  Blood Primary Author:  Peffault ... During the study, six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by ...

    Research Article last updated 01/20/2015 - 2:28pm.

  3. Clone of Patients

    ...

    Page last updated 03/14/2016 - 6:05pm.

  4. AAMDSIF Summer Fellowship Grant Program

    ... (BM) characterized by profound decrease of the number of red blood cells, white blood cells, and platelets in the blood stream, leading to ...

    Page last updated 05/17/2017 - 1:29pm.

  5. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

    ... dependency (defined as having received at least one red blood cell transfusion every 8 weeks over a period of 4 months), Eastern ...

    Research Article last updated 11/10/2015 - 10:47am.

  6. Eltrombopag Added to IST Yields Encouraging Results

    ... improvement in platelet counts but also noticed recovering red and white blood cells numbers. Although the magnitude of the response was somewhat ...

    Interview last updated 05/24/2017 - 7:44am.

  7. The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes

    ... patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose ...

    Research Article last updated 06/02/2014 - 11:03am.

  8. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    Journal Title:  Blood Primary Author:  Itzykson ... cytogenetics , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) ...

    Research Article last updated 07/28/2014 - 8:53am.

  9. A novel marker for screening paroxysmal nocturnal hemoglobinuria using routine complete blood count and cell population data

    ... marker. METHODS: We analyzed 979 complete blood counts (CBC) data from 963 patients including 57 data from 44 PNH ... were followed: flow cytometry for CD55 and CD59 on red blood cells (RBCs) to a detection level of 1%; and fluorescent aerolysin, ...

    Research Article last updated 03/02/2015 - 11:39am.

  10. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... that lenalidomide is effective not only in reducing red blood cell (RBC) transfusion burden, but also in modifying the disease ...

    Research Article last updated 12/08/2015 - 1:06pm.